Achillion Pharmaceuticals

INVESTORS

Press Releases

 
Press Releases
  Date Title View
Feb 28, 2017
Three-year study commenced to include up to 400 patientsNatural history studies track course of a disease over time; can inform and support development and approval of new treatments for patientsC3 glomerulopathy currently has no cure or approved treatment; affects about 8,000 people acr...
PDF
Feb 23, 2017
Complement factor D inhibitor program on track for initiation of ACH-4471 phase II trial for treatment-naïve PNH patients during the first half of 2017Expanding complement platform includes internally discovered next-generation oral factor D inhibitors with the goal of advancing at least one into clinical...
PDF
Feb 13, 2017
NEW HAVEN, Conn., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Leerink Partners 6th Annual Global Healthcare Conference on Th...
PDF
Dec 28, 2016
NEW HAVEN, Conn., Dec. 28, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it has received a $15 million milestone payment from Janssen Research & Development, LLC., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), related to enrollment...
PDF
Dec 5, 2016
SAN DIEGO, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced novel research into complement biology that both expands the understanding of this important emerging area and demonstrates the potential advantage of factor D inhibitors like the company's lead candidate, ACH-4471...
PDF
Nov 30, 2016
- Janssen initiates dosing of patients in OMEGA-1: Phase 2b study evaluating six- and eight-week treatment durations with JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335, for the treatment of chronic HCV - NEW HAVEN, Conn., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Ac...
PDF
Nov 3, 2016
NEW HAVEN, Conn., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts have been accepted for poster presentation at the 58th Annual Meeting of the American Society of Hematology (ASH) in S...
PDF
Nov 3, 2016
Janssen HCV triple combination candidate JNJ-4178 reported 100% SVR12 after 6 weeks of therapy; global phase IIB study to begin 4Q 2016Achillion's phase I MAD study with oral factor D inhibitor ACH-4471 ongoing; strong complement inhibition observed in in vivo and ex vivo assays Company ...
PDF
Nov 2, 2016
NEW HAVEN, Conn., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the 25th Annual Credit Suisse Healthcare Conference on Monday, N...
PDF
Sep 23, 2016
- ePoster presented today at the EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection — The Roadmap For Cure - - Ongoing Phase 2 development focusing on triple combination for treatment durations as short as six weeks for broad HCV population —...
PDF
FirstPrevious
2
...
NextLast